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background. Natural populations of T. cruzi have 
been classified into six phylogenetic lineages or 
discrete typing units, T. cruzi I, IIa, IIb, IIc, IId, and 
IIe, believed to play a role in tissue tropism and 
disease pathogenesis. The impact of HIV infection 
in the T. cruzi genetic diversity in coinfected pa-
tients is a scarcely explored field of parasitology. 
Objective. To characterize parasitic lineages in 
clinical samples from patients co-infected with T. 
cruzi and HIV 
Materials and Methods. We analyzed blood 
and lesions samples from 25 patients residing 
in Argentina, namely 8 infants born to 7 HIV 
- T. cruzi co-infected mothers, 3 indeterminate 
adult chagasic patients with HIV co-infection 
and 7 presenting cerebral Chagas due to AIDS. 
Molecular diagnosis and monitoring of etiological 
treatment was carried out by PCR targeted to 
kinetoplastid (kDNA) and/or satellite sequences. 
T. cruzi lineages were identified by means of PCR 
targeted to the intergenic spacer of miniexon gene 
and 24s ribosomal ARN genes. To characterize the 
infra-lineage diversity, restriction fragment length 
polymorphism (RFLP) of KDNA amplicons was 
carried out.
results. Out of the 7 co-infected mothers, two 
transmitted both HIV and T. cruzi to their siblings, 
four transmitted only T. cruzi. The remaining case 
was a pregnant woman with cerebral Chagas dis-
ease who entered into a coma being treated with 
benznidazole; she did not transmit congenital 
Chagas disease nor HIV to her newborn. 
Most bloodstream populations belonged to T. 
cruzi IId, with unique minicircle signatures for 
each patient´s strain, but identical signatures be-
tween strains from mothers and their congenitally 
infected infants. Mixtures of lineages T. cruzi I 
and T. cruzi IId were also detected. Differential 
tissue tropism of T. cruzi IIb and T. cruzi I was 
found in patients with cerebral chagas. Minicircle 
signatures showed complex patterns suggestive of 
polyclonal populations.
Conclusions. The higher proportion of PCR 
positive samples suggests higher parasite loads 
that in chagasic population without HIV. The 
higher prevalence of T. cruzi IId in bloodstream 
is in agreement with previous findings in this 
region. The association of rare lineages at sites 
of encephalytis suggests differential tropism. 
The direct characterization of parasite lineages in 
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clinical samples allowed identification of a higher 
prevalence of mixed infections, than previously 
assumed, from studies based on culture isolates. 
Keywords: Trypanosoma cruzi, Chagas disease 
reactivation, kinetoplastid DNA, parasite lineage, 
tissue tropism, HIV, AIDS 
rEsUMEN
Linajes de Trypanosoma cruzi en pacientes con 
enfermedad de Chagas y coinfección por VIH
Introducción. Las poblaciones naturales de T. cruzi 
han sido clasificadas en seis linajes filogenéticos 
o unidades de tipificación discreta: T. cruzi I, IIa, 
IIb, IIc, IId y IIe, que pueden jugar un rol en el 
tropismo tisular y patogénesis de la enfermedad 
de Chagas. El impacto de la infección por VIH 
en la diversidad genética de T. cruzi en pacientes 
coinfectados es un campo poco explorado en 
parasitología.
Objetivo. Caracterizar linajes de poblaciones para-
sitarias naturales en muestras clínicas de pacientes 
coinfectados por T. cruzi y VIH.
Materiales y Métodos. Se analizaron muestras 
de sangre y/o lesiones de 25 pacientes residentes 
en Argentina: 8 pediátricos nacidos de 7 madres 
coinfectadas, 3 adultos con Chagas indeterminado 
y VIH y 7 con encefalitis chagásica por SIDA. El 
diagnóstico molecular y seguimiento de tratamien-
to etiológico se realizó por PCR hacia secuencias 
del minicírculo y/o satélite. Los linajes de T. cruzi 
fueron identificados por PCR para fragmentos 
de genes para miniexón y ARN ribosomal 24s. 
La diversidad infra-linaje fue caracterizada por 
polimorfismo de fragmentos de restricción de las 
regiones variables del minicírculo.
resultados. De las 7 madres coinfectadas, 2 
transmitieron tanto VIH como T. cruzi a sus hijos 
y 4 sólo transmitieron T. cruzi. El otro caso fue 
una mujer embarazada que al entrar en coma por 
presentar un cuadro de Chagas cerebral fue tratada 
con Benznidazol y no transmitió ni Chagas ni 
VIH a su hija. En los casos tratados se observó 
la negativización de la PCR. La mayoría de las 
poblaciones parasitarias sanguíneas fueron T. 
cruzi IId, con perfiles de minicírculos particulares 
de cada paciente, excepto en pares madre-niño 
infectados, en que resultaron idénticas. Se 
hallaron poblaciones mixtas con T. cruzi I-IId. 
En pacientes con reactivación chagásica se 
encontró tropismo diferencial de T. cruzi IIb y T. 
cruzi I en lesiones. En estos pacientes los perfiles 
de minicírculos mostraron patrones complejos 
sugiriendo poblaciones policlonales.
Conclusiones. La elevada proporción de muestras 
PCR positivas es indicativa de cargas parasitarias 
más elevadas que en población chagásica sin VIH. 
Esta exacerbación estaría también implicada en la 
alta tasa de transmisión vertical. La prevalencia 
de linaje IId en sangre periférica concuerda con 
lo hallado en población chagásica en la región. 
La asociación de linajes infrecuentes en lesiones 
asociadas a encefalitis chagásica sugiere tropismo 
diferencial. El análisis directo de linajes parasi-
tarios en muestras clínicas permitió detectar una 
mayor prevalencia de infecciones mixtas que la 
detectada a partir de aislamientos en cultivo.
INtrODUCtION
Chagas disease is a serious, potentially 
life-threatening illness caused by a protozoan 
parasite called T. cruzi. It occurs mainly in Latin 
America where, during the 1980s, over 20 million 
people were thought to be infected. Since then, 
Latin American countries have made enormous 
efforts to control the infection, such that current 
estimates suggest that less than 8 million people 
remain infected (1). Due to social and economical 
restrictions in endemic countries, individuals from 
rural endemic areas have migrated to urban centers, 
leading to the urbanization of Chagas disease. 
More recently, cases have been identified in non-
endemic countries in Europe, and in Canada and 
the United States. In urban areas the pandemics 
of acquired immunodeficiency syndrome (AIDS) 
is more prevalent and has opened the appearance 
of Chagas disease reactivation in individuals 
seriously immunocompromised by the human 
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immunodeficiency virus (HIV) and co-infected 
with T. cruzi (2-7). During reactivation, T. cruzi 
is persistent in the blood and it invades most 
frequently the central nervous system and the 
heart (2-4, 8-12). Cerebral chagomas show focal 
necrotic lesions indistinguishable from those 
caused by Toxoplasma gondii, so are frequently 
treated as cerebral toxoplasmosis (13). 
The impact of HIV infection in the progression 
and severity of a previous T. cruzi infection is a 
poorly explored field of clinical parasitology. 
Natural populations of T. cruzi are composed of 
multiple clones, most of which are distributed into 
six phylogenetic lineages or discrete typing units 
(DTUs), designated as T. cruzi I, IIa, IIb, IIc, IId 
and IIe (14, 15) and recently renamed as T.cruzi 
I, IV, II, III, V and VI, respectively (16). T. cruzi 
I has a very large geographical distribution from 
North to South America, predominating in the 
Amazonian basin northwards, where domestic and 
sylvatic triatomines are involved in transmission 
in several endemic regions from Venezuela, 
Colombia, Central America and Mexico (17, 18). 
In these countries, T. cruzi I infects patients and 
different pathological forms have been observed 
(19-22). 
However, information regarding the clinical 
relevance of this parasite lineage in the southern 
cone of America is scarce. Recent molecular 
evidence based on microsatellite typing allowed 
mapping the high heterogeneity of T. cruzi I 
populations and attempts to classify them based 
on nuclear genes are currently undergone (23-25). 
In contrast, T. cruzi IIb, IId and IIe populations are 
known to circulate predominantly in the southern 
cone of America, causing vectorial and congenital 
Chagas disease (26, 27). 
In the present study, we aimed to characterize 
the main parasitic DTUs detectable in blood from 
indeterminate Chagas disease patients with HIV 
co-infection, and in both blood and tissue lesions 
in those presenting clinical reactivation due to 
AIDS. 
MatErIaLs aND MEtHODs
Patients
Patients were admitted for diagnosis, treat-
ment and follow-up at diverse health centers in 
the metropolitan area of Buenos Aires city, not 
endemic for Chagas disease, namely Hospital 
Ignacio Pirovano, Hospital Eva Perón, Hospital 
Francisco Santojanni, Hospital Carlos Durand, 
Hospital Ricardo Gutiérrez and Hospital Juan A. 
Fernández.
Clinical samples were referred to LabMECh 
at INGEBI for molecular diagnosis and typing of 
T. cruzi populations.
This study fulfilled all criteria required 
by the Medical Code of Ethics and the Helsinki 
II statement and was approved by the Review 
Boards of the participating Institutions. Written 
informed consents were obtained directly from 
the patients.
Laboratory diagnoses 
Routine serological assays for T. cruzi 
and Toxoplasmosis, histopathological studies, 
Microhematocrite, Strout tests and direct 
observation of trypomastigotes or amastigotes 
were performed in each health center taking care 
of each patient, following their current diagnostic 
practices (18). T1 and T2 weighted magnetic 
resonance imaging and cerebral Computerized 
Axial Tomography (CAT) scan with contrast were 
done at each center taking care of those patients 
with suspicion of cerebral reactivation disease. 
Molecular characterization of natural parasite 
populations
The natural populations of T. cruzi 
detected in peripheral blood and tissue samples 
were characterized using different molecular 
approaches. 
All blood and some cerebrospinal fluid 
samples were mixed with an equal volume of 
Guanidinium 0.6 M - EDTA 0.2 M pH 8.00 buffer, 
let stand at room temperature overnight and boiled 
for 15 minutes prior to DNA extraction with 
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phenol-chlorophorm, followed by isopropanol 
precipitation, as detailed in previous studies of 
blood samples (27). 
Some cerebrospinal fluid samples, fresh, 
or paraffin-embedded brain biopsy samples were 
processed using the QiAMP mini kits for fluids 
or tissues (Qiagen, USA), as described before 
(28,29). 
amplification of repetitive sequences for 
molecular detection of T. cruzi DNa
PCR targeted to the high variable region of 
the multicopy minicircles (k DNA) was done using 
primers 121 and 122 and Taq Platinum polymerase 
(Invitrogen, USA) for hot start-PCR as reported 
elsewhere (27).
PCR targeted to the tandemly repeated 
nuclear satellite sequence was done as a confir-
matory test in some cases, using primers cruzi 1 
and cruzi 2 (30) by Real Time PCR. Briefly, the 
mixture contained Taq Platinum buffer 1x, MgCl2 
3 mM, dNTPs 0.25 mM, oligonucleotides cruzi 
1 (5´- ASTCGGCTGATCGTTTTCGA- 3´) and 
cruzi 2 (5´- AATTCCTCCAAGCAGCGGATA 
- 3´) 0.5 μM each, Sybr Green 0.5 x,  Taq DNA 
polymerase platinum 5 U/ μl (Invitrogen, USA) 
0.5 Units in a final volume of 20 uls. Cycling 
conditions were 94ºC during 5 min, and then 40 
cycles of 94 ºC 10 seconds, 58 ºC 10 seconds and 
72 ºC 10 seconds in  a Rotor–Gene ™ Real Time 
Thermocycler (Corbett Life Science’s, Australia). 
The fluorescence was read at the end of each cycle 
at 80 ºC. Negative kDNA or sat-DNA findings 
were confirmed by amplification of apolipopro-
tein B human gene fragment (ApoB) in order 
to discard loss of material or carry over of PCR 
inhibitors. This was done by Real time PCR, us-
ing primers ApoB Fw (5´- TGGCAACACCAG-
CACAGACCATTTCAGC-3´) and ApoB Rv (5´-
GTAGGAAAGCAGGTCAACCACAGAGTCAG 
-3´) at a final concentration of 1 μM, with the 
remaining PCR reagents and cycling conditions 
as for T. cruzi real-time-PCR except that the tem-
perature of annealing was 65 ºC. 
PCR based identification of discrete typing 
units
Trypanosoma cruzi DTUs were investigated 
in all kDNA or Satellite DNA positive clinical 
samples using lineage-specific nuclear genomic 
markers, including the intergenic region of the 
spliced leader genes (SL-IR), the D7 domain of 
the 24s alpha ribosomal RNA genes (24S rDNA) 
and the A10 fragment, using heminested hot-start 
conventional PCR or Real time PCR as described 
elsewhere (27). In order to confirm the identity of 
unusual DTUs in our study patients, the SL-IR and/
or 24s rDNA fragments from the corresponding 
amplicons were purified in Qiagen columns and 
sequenced. Alignment with homologous sequences 
from reference T. cruzi stocks representing the 
different DTUs was done using Mega Software. 
Genbank accession numbers were AS FJ713356 
and GQ303145.
Profiling of minicircle signatures
Two micrograms of kDNA-PCR products, 
purified from preparative agarose gels, were 
subjected to restriction fragment length 
polymorphism (RFLP) PCR, using 5 units of 
MspI plus RsaI or AluI plus HinfI during 3 hours at 
37ºC, as previously described (27). The digestion 
products were analysed by electrophoresis in 10% 
polyacrylamide gel stained with silver nitrate or 
Sybr green dye.
rEsULts 
Chagas disease mothers co-infected with HIV 
and transmission of congenital Chagas dis-
ease
Seven HIV positive Argentinean mothers 
with T. cruzi infection and their 8 children were 
included in the study; their epidemiological data 
are shown in table 1. Case one was studied during 
pregnancy and at delivery, case 2 was studied at 
delivery and the remaining ones were studied when 
their infants were refereed to Hospital Ricardo 
Gutierrez for diagnosis of congenital infection 
(table 1). Cases 2 and 5 transmitted HIV and T. 
bisio et al.
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cruzi to their siblings, cases 3, 4, 6 and 7 transmitted 
only T. cruzi congenital infection whereas case 1 did 
not transmit any of both pathogens. Interestingly, 
case 1 was a pregnant woman vectorially infected 
at a highly endemic locality of Argentina, who 
developed chagasic encephalitis at her 31d week 
of pregnancy and consequently was treated with 
benznidazole (5 mg/kg/day) for 90 days followed 
by prophylaxis (5 mg/kg/day thrice a week) with 
favorable outcome. PCR for T. cruzi k DNA 
was positive in pre-treatment blood samples and 
became negative in samples tested seven weeks 
after treatment initiation, persisting PCR negative 
during post-treatment prophylaxis. Furthermore, 
seroconversion to negative was identified from 
serum samples collected 16 weeks after treatment 
initiation. Serological analysis of a cerebral 
spinal fluid (CSF) sample taken two months after 
treatment initiation also gave negative results (data 
not shown). It is noteworthy that her newborn was 
not infected by T. cruzi as diagnosed by means of 
Microhematocrite and PCR at delivery and at 4 
weeks of age, and did not acquire HIV infection. 
Negative serology against T. cruzi at 12 months 
of age allowed discarding congenital infection 
(table 1). 
Trypanosoma cruzi and HIV co-infections by 
syringue-mediated drug sharing among inject-
ing drug users 
Two patients (cases 8 and 9, table 2) were 
detected as seropositive for T. cruzi among 87 
IDU individuals co-infected with HIV, who were 
diagnosed at the Service of Hospital Santojanni 
among 328 HIV positive individuals screened 
between January 2000 and October 2005. Both 
cases were men born and living in Buenos Aires 
city, who did not have any contact with triatomine 
bugs, nor received blood transfusions and in one 
of them the seronegativity of her mother was 
investigated, allowing discard congenital infection. 
However, both patients shared syringues. PCR 
for kDNA and Sat-DNA were positive in blood 
samples and T. cruzi IId was identified in both 
cases (table 2). Follow-up of these patients was 
not accomplished because they did not go back to 
the health center.
Cerebral Chagas reactivation in aIDs pa-
tients
Eight HIV positive patients were referred 
for molecular diagnosis of chagasic infection or 
for differential diagnosis of Chagas reactivation 
because of encephalitis and brain tumor masses 
in order to initiate their etiological treatment with 
benznidazole (Cases 10 to 17, table 2, example in 
Figure 1). Cases 10 to 12 were reactive or nearly 
the cut-off line for anti-Toxoplasmosis serological 
analysis and also seropositive for Chagas disease; 
hence they were initially treated for cerebral toxo-
plasmosis. Anatomo-pathological observation of 
cerebral biopsy samples, microscopic observation 
of cerebrospinal fluid and/or Strout tested on their 
peripheral blood failed to give a precise diagnosis 
of T. cruzi infections in all these cases, except 
in case 12, who was Strout positive. Thus, final 
diagnosis of chagasic reactivation was assessed 
with the aid of k DNA and/or Real Time Sat-DNA 
PCR findings from brain biopsy or cerebrospinal 
fluid samples (example for case 12 in Figure 2), 
allowing initiation of their parasiticidal treatment 
with benznidazole. 
Direct identification of T. cruzi DtUs in clinical 
specimens of HIV positive patients
Trypanosoma cruzi DTUs were investi-
gated in kDNA or Sat-DNA PCR positive clinical 
samples using PCR procedures. Their findings are 
depicted in tables 1 and 2. The parasite DTUs 
were identified in most samples. T. cruzi IId was 
found in all positive blood samples, except in two 
that presented mixtures with T. cruzi I; one of 
them belonged to a newborn from an HIV positive 
mother (case 5I, table 1) and the other one to a 
41 year-old bolivian immigrant with AIDS reac-
tivation (case 11, table 2). In the latter case, the 
cerebrospinal fluid sample amplified only T. cruzi 
I (table 2). It is noteworthy that in case 10, brain 
Trypanosoma cruzi lineages and HIV co-infection
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biopsy samples amplified T. cruzi IIb populations 
and not the bloodstream T. cruzi IId, suggesting 
differential tissue tropism. These unusual DTUs 
were further confirmed by sequencing of the 24s 
alpha rDNA fragment from brain tissue of case 
10 and of the SL-IR fragment from the amplicon 
obtained from the CSF sample of case 11.  
In the other patients with encephalitis in 
which the parasites DTUs could be assessed, they 
belonged to T. cruzi II b/d/e or T. cruzi IId popula-
tions (example in table 2 for case 12). 
Fingerprinting of minicircle signatures of 
parasitic populations 
Characterisation of parasite genetic diversity 
at the infra-lineage level was also done from k 
DNA PCR positive samples obtained from these 
patients. The minicircle signatures were unique 
for each case, even among those ones infected 
with the same parasite lineage (Figure 2a), but 
were almost identical between maternal and 
neonatal populations in those cases with congenital 
transmission of T. cruzi (cases 2 and 4 of table 
1, Figure 2). 
Comparison of minicircle signatures from 
the tested patients´ samples with those from 
reference parasite clones from the corresponding 
DTUs allowed observation of a larger number 
of restriction fragments in populations from the 
HIV positive patients, indicating that patients´ 
populations were more complex, suggesting 
polyclonality (Figure 2). 
DIsCUssION 
HIV and vertical transmission
Several authors have reported the vertical 
T. cruzi transmission rates ranging from 2% to 
10.4% (31, 32). Previous studies suggested that 
T. cruzi parasitemia during pregnancy correlates 
with the risk of vertical transmission (27, 33, 34). 
Accordingly, HIV and T. cruzi co-infected mothers 
would present a higher risk of vertical transmis-
sion of T. cruzi (35). There is scarce information 
regarding vertical transmission of T. cruzi from 
bisio et al.
Figure 1. report of case 13 with Chagasic encephalitis 
a. t1-weighted MrI (left) showing hypotense lesion with 
perilesional edema in t2 sequence (right). b. t1-weighted 
MrI with gadolinium showing cystic like hipotense lesion 
with peripheric annular enhancement. C. Dissociation 
peaks of Sybrgreen-fluorescent amplified DNAs from T. 
cruzi satellite sequence (C, 82.4°C) and D. apolipopro-
tein-b human gene (D, 82.2°C) obtained after real time 
PCr from brain biopsy sample. Patient`s samples appear 
as the lower peaks and positive controls (PC) (C: T. cruzi 
II CL-brenner DNa, D: DNa from Jurkat cells) as the 
higher peaks. E and F: agarose gel electrophoresis show-
ing (E) the 425 bp product from the intergenic region of 
T. cruzi lineage II miniexon genes (burgos et al, 2007): 
Lane 1, patient’s cerebral tissue sample; lane 2, T. cruzi 
II reference stock; lane 3, 1 Kbp DNa molecular weight 
marker and (F) 140 bp and 125 bp fragments from the 
24sα rDNa D7 domain: Lane 1,100 bp DNa molecular 
weight marker; lane 2, patient’s cerebral tissue sample; 
lane 3, T. cruzi IId reference stock;  lane 4, T. cruzi IIb 
reference stock 
Figure 2. a) Comparison of rFLP-PCr based minicircle 
signatures, after double digestion of the 330 bp kDNa 
amplicon with Msp I-rsa I from T. cruzi IId bloodstream 
parasite populations from cases 2 and  4 (table 1) and 
8 and 9 (table 2) as well as reference clones for T. cruzi 
II DtUs, namely tc IIa (CaN III), tc IIb: (tu 18); tc 
IIc: (M5631), tc IId (MnCl2) and tc IIe (Cl- brenner). 
M; Molecular weight marker. b) Comparison of rFLP-
PCr based minicircle signatures digested by alu I–Hinf 
I and Msp I-rsa I from T. cruzi IIb parasite populations 
of cerebral chagoma from case 10 (lanes 10) and T. cruzi 
IIb (lanes IIb) reference clone tu 18 cl2. M, 10 bp DNa 
ladder
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HIV positive pregnant women at the indeterminate 
or chronic phases of T. cruzi infection (36, 37).  In 
this study HIV positive women were all kDNA-
PCR positive, whereas the same PCR procedure 
allowed detection of 64.5 % of aged-matched non-
HIV women at the indeterminate phase of Chagas 
disease (27). It is remarkable that the only HIV 
and T. cruzi co-infected mother who delivered a 
non-infected newborn was treated with benznida-
zole during gestation due to encephalytis (case 1, 
table 1).
Chagas disease and drug abuse mediated 
transmission
Both cases 8 and 9 were detected among 
HIV infected patients with antecedents of 
injecting drug use and seropositivity for anti-T. 
cruzi antibodies at Hospital Santojanni. In that 
health center, the prevalence of seropositivity for 
T. cruzi was only one out of 247 among non-IDU 
patients with HIV infection screened individuals, 
but three among 87 IDU screened cases with HIV 
infection [p=0,048; RR=9,15 (0,96<RR<86,73) 
(Scapellato P, personal communication). The 
higher prevalence of HIV-T. cruzi co-infection 
among IDU individuals has recently been reported 
in other cohort from Argentina (38).Transmission 
of parasitic diseases through IDU also has been 
demonstrated in parasite diseases such as Malaria 
and Leishmaniosis (39), but not in Chagas disease. 
Transmission of Chagas disease by inoculation 
of low quantities of infected fluids, such as in 
laboratory accidents has been reported (40). 
Given that a proportion of indeterminate Chagas 
disease patients harbor patent parasitemia and that 
transfusional transmission from indeterminate 
Chagas disease patients occurs (40, 41), it is 
tempting to speculate that sharing needles could 
be another plausible route of transmission. Sartori 
et al. (42) found higher parasitemias in chagasic 
patients with HIV that in non-HIV carriers. All 
together, these data suggest that Chagas disease 
could be transmitted among IDU patients with 
HIV co-infection.
Cerebral Chagas reactivation in aIDs 
patients
The first published case of cerebral Chagas 
disease is dated in 1990 and consisted of an oc-
cupying cerebral mass, designated as cerebral 
chagoma in an immunosuppressed hemophylic 
patient (43). Cerebral Chagomas may present int-
ralesion bleeding (44) and amastigote nests in glial 
and endothelial cells (45). Rapid specific diagnosis 
leading to prompt specific treatment and surgical 
evacuation of cerebral lesions may aid to a better 
evolvement of these patients (3, 46-52). Although 
in the majority of the patients so far reported with 
cerebral reactivation, there are no data regarding 
their immunologic status, but it is possible to 
presume that Chagas reactivation tends to occur, 
similarly to what is seen with other opportunistic 
infections in AIDS, when the T-CD4 lymphocyte 
count is below 200 cells/mm3. In fact, in 10 previ-
ously reported cases where this information was 
available (3), the number of T CD4 lymphocyte 
number varied from 35 to 382 cells/mm3, and in 
seven of them the levels were below 200 cells/
mm3. A recent study of 15 patients, Cordova et al 
(12) reported a median CD4 T-cell count at time 
of reactivation of  64 cells/μl (range 1-240) with 
77% of patients presenting <100 CD4 T- cells/
μl, as was the case for  patients 10 and 11 of  our 
study, from whom this information was available 
(table 2).  
Differential Diagnosis of Cerebral Chagas 
disease 
Concurrent cerebral Chagas disease and 
Toxoplasmosis was reported in a patient with 
AIDS (47). However in some cases, specific para-
site forms are difficult to be recognized by con-
ventional histopathological analysis. Thus, PCR 
targeted to kDNA or satellite sequences, which are 
highly repetitive and therefore allow detection of 
low parasitic numbers, have shown their usefulness 
for differential diagnosis of Chagasic encephalytis 
(table 2, 29, 46). In our more recently analysed 
cases, a novel Real time PCR approach targeting 
Trypanosoma cruzi lineages and HIV co-infection
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the satellite DNA sequence was implemented, 
which has the advantage of not requiring post-PCR 
gel electrophoresis for product visualization, thus 
reducing amplicon carry-over contamination in the 
laboratory (Figure 1). Moreover, it can provide a 
quantitative measurement of the parasitic load in 
the tested sample (53, 54). It is expected that, once 
standardized, this Real Time PCR may become a 
useful diagnostic tool to resolve further clinical 
cases of difficult diagnosis. Future research to-
wards the simultaneous molecular detection of 
T. cruzi, T. gondii and Epstein Barr virus (EBV) 
sequences in a single Real Time Multiplex PCR 
reaction should provide a useful tool for prompt 
resolution of these cases. 
Moreover, the application of Quantitative 
Real Time PCR strategies may be used to follow-
up patients under treatment with benznidazole 
(54) or novel parasiticidal drugs as well as to aid 
physicians in the management of patients under 
prophylaxis and in establishing criteria of cure. 
T. cruzi DtUs in HIV positive patients 
Previous reports that compared zymodemes 
of parasite stocks obtained from HIV positive 
patients with T. cruzi co-infection did not reveal 
significant differences regarding the tissue tropism 
or repartition of the strains (55). In our cohort, all 
patients showed T. cruzi IId populations in blood-
stream, except two cases, 5I and 11 that presented 
co-infections by T. cruzi IId and T. cruzi I. T. cruzi 
IId is the most frequently found lineage in blood 
samples of indeterminate Chagas disease patients 
from the southern cone of America (27). Cases 10 
and 11 correspond to patients with a differential 
distribution of T. cruzi populations associated to 
reactivation. Consequently, their parasitic popula-
tions were further characterized using additional 
molecular tools, such as microsatellite typing 
and polymorphism of the kDNA (Figure 2 B, 29, 
46). 
Moreover, the presence of T. cruzi IIb popu-
lations in case 10, as identified by means of 24sα 
rDNA and A10 based amplification strategies (27, 
56) was confirmed by sequencing of the 24sα 
rDNA amplicon. The characterization of T. cruzi 
nuclear DNA sequences from clinical specimens 
provides a starting point to determine the genomic 
structure of the parasite populations linked to hu-
man tissue tropism and disease.  
This report also illustrates that T. cruzi I 
infections are found in patients of the southern 
cone of America, suggesting that this lineage 
is more prevalent than previously assumed in 
these countries (57). This DTU was confirmed 
by sequencing analysis of the SL-IR amplicon 
obtained from the CSF sample from case 11. The 
very low prevalence of T. cruzi I in the general 
population of southern America suggests that their 
strains would display lower levels of parasitic loads 
than T. cruzi II strains, at least at the indeterminate 
or chronic phases of Chagas disease. Indeed, the 
study of HIV positive patients together with the 
direct molecular analysis of blood and tissue 
samples linked to clinical reactivation brought 
to light the occurrence of mixed infections 
including T. cruzi I genotypes that caused severe 
disease (29).  
Fingerprinting of minicircle signatures of 
parasitic populations 
The analysis of the minicircle signatures us-
ing double digestion of kDNA amplicons provided 
evidence of the heterogeneity of populations be-
longing to a same DTU (cases 2, 4, 8 and 9) which 
were particular of each patient, except for those 
present in mothers and their congenitally infected 
siblings that depicted nearly identical populations, 
as was extensively discussed in a previous work 
(26). Comparing with minicircle signatures of 
reference T. cruzi clones, the patients´populations 
showed a larger number of minicircle fragments 
that reflect different minicircle subclasses indica-
tive of polyclonal populations. Indeed, some of 
these patients´ populations were subjected to 
analysis of polymorphism of microsatellite loci 
(58) and in most of them more than two microsatel-
lite alleles were detected for different loci, which is 
bisio et al.
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indicative of polyclonal strains (29, 46, 58). These 
findings suggest that the immunological status 
plays a role in the constraint of circulating sub-
populations in bloodstream, giving rise to atypical 
variants and in some cases to unusual tissue loca-
tions in immunosuppressed patients. This was also 
observed in HIV positive patients co-infected with 
other protozoan organisms, such as Leishmania sp. 
and lower trypanosomatids (59, 60).
Finally, this report illustrates the usefulness 
of molecular strategies for diagnosis of Chagas 
reactivation in AIDS patients, as well as for 
epidemiological studies of T. cruzi and HIV co-
infections.
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